VEGF, >90% (SDS-PAGE), recombinant, expressed in NSO cells, lyophilized powder

Stock Code: 3593856
Manufacturer Part No: V6758-50UG

Order Now for 7 day delivery

Click Add to Quote for price and delivery

Quantity: - +

Descriptions

Analysis Note

The biological activity is measured by its ability to inhibit the VEGF-dependent proliferation of human umbilical vein endothelial cells.

Application

VEGF Receptor-2 (Flk-1, KDR)/Fc Chimera human is a homodimeric protein contains extracellular domain of human VEGF R2 (KDR) fused to the 6x histidine tagged Fc portion of human IgG1 by the peptide (EGF). The product was used to stuyd vasculogenesis and angiogenesis and as marker for pluripotent hematopoietic stem cells.

Biochem/physiol Actions

VEGF Receptor-2 (VEGF R2) also known as Flk-1 or KDR belongs to class III subfamily of RTKs is a potent VEGF antagonist and is mainly expressed in endothelial cells. VEGF R2 can stimulate PLC-gamma pathway which in turn activate MAP kinase and subsequent strong signalling as well as can partly induces mitotic signals in NIH3T3 fibroblasts. KDR also facilitates the release of nitric oxide in endothelial cells and assist in the regulation of the vasculature.

VEGF receptors, class III receptor tyrosine kinases, have seven Ig like extracellular motifs and a tyrosine kinase intracellular domain split by a kinase insert sequence. VEGFR 1 and 2 are both expressed in an endothelial cell-specific manner.

Physical form

Lyophilized from a 0.2 µm filtered solution in phosphate buffered saline containing 2.5 mg bovine serum albumin.